David Sinclair/X
May 4, 2026, 17:00
David Sinclair: NMN Modulates Immune Response in Antibody-Mediated Bleeding Disorder
David Sinclair, Author and Host of Lifespan, shared a post on X about a recent article by Huiyuan Li et al., published in Nature, adding:
”New Clinical Trial Result:
NMN suppresses harmful antibody-driven immune attacks to alleviate a common bleeding disorder. Authors suggest it may help other autoimmune diseases like lupus and rheumatoid arthritis.”
Title: Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial
Authors: Huiyuan Li, Yuan Xu, Yunfei Chen, Lulu Ji, Yanmei Xu, Wenting Zheng, Ting Sun, Rongfeng Fu, Xiaolei Pei, Xiaofan Liu, Feng Xue, Wei Liu, Wentian Wang, Ying Chi, Renchi Yang, Jun Wei, Lei Zhang
Stay updated on all scientific advances with Hemostasis Today.
-
May 14, 2026, 11:41Omer Mohammed: Functional Benefits and Bleeding Risks in Stroke Bridging Therapy
-
May 14, 2026, 06:39Khushali Pandit: Innovations in Cell Therapy Manufacturing Highlighted at ISCT 2026
-
May 14, 2026, 06:09Sophia Delicou: A Shift Toward Function-Centered Care for Patients with Hemoglobinopathies
-
May 14, 2026, 06:04Tim Grisham: The Lasting Impact of Nurses in Hemophilia Care and Care Continuity
-
May 14, 2026, 05:19Tackling Cardiovascular Comorbidities in Bleeding Disorders – EHC
-
May 13, 2026, 17:38Rohit Sankar J. Snscphysio: Recognizing the Clot Before It Becomes Life-Threatening
-
May 13, 2026, 16:41Seema Dawood: When Elevated Platelets Signal a Myeloproliferative Neoplasm
-
May 13, 2026, 16:38Kari Tikkinen: Defining Thromboprophylaxis in MIBC Neoadjuvant Care
-
May 13, 2026, 16:28Nadia Tarhini: Evaluating the Risk of Recurrent Thrombosis in Children with ALL